Phaseline

Targets › POLA1

POLA1 (DNA polymerase alpha catalytic subunit): drug programs, companies and trials

11 programs from 11 companies in 47 trials: 28 Phase 2, 14 Phase 1, 5 Phase 3; Oncology, Neurology, Infectious disease; next expected readout Dec 2026.

Catalytic subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, a regulatory subunit POLA2 and two primase subunits PRIM1 and PRIM2) is recruited to DNA at the replicative forks via direct…. (UniProt, P09884)

Open in Phaseline: the race on POLA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jiangsu Healthy Life Innovation Medical TechnologyGemcitabine hydrochloride
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 3Locally Advanced Pancreatic Cancer; Clear Cell Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian Brenner Tumor …Dec 2026
Gilead SciencesTenofovir Disoproxil Fumarate
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLA1, POLBPhase 3Chronic Hepatitis B; Hepatitis B; Hepatitis B Infection; Parkinson DiseaseJul 2027
Memorial Sloan Kettering Cancer CenterClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2AMLDec 2026
Dana-Farber Cancer InstituteClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Langerhans Cell HistiocytosisDec 2026
M.D. Anderson Cancer CenterClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Recurrent Acute Lymphoblastic LeukemiaAug 2027
City of Hope Medical Centerclofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Adult Acute Lymphoblastic Leukemia in RemissionAug 2027
West China Second University HospitalClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Langerhans Cell Histiocytosis (LCH)Jun 2028
Nantes University HospitalClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Acute Myeloid Leukemia in RemissionSep 2028
Princess Maxima Center for Pediatric OncologyClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1Relapsed Pediatric AMLDec 2026
Ekaterina LaukhtinaClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1Advanced Urothelial CarcinomaNov 2028
Beijing Immunochina Medical Science & TechnologyFludarabine Phosphate (IM19)
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1NHL; B-cell Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Refractory Idiopathic Aplastic Anemia …Jun 2035

Conditions

Acute Myeloid Leukemia in Remission (2) Acute Myeloid Leukaemia (AML) (2) Cancer (2) Metastatic Pancreatic Adenocarcinoma (2) Recurrent Acute Lymphoblastic Leukemia (1) Langerhans Cell Histiocytosis (1) NHL (1) B-cell Acute Lymphoblastic Leukemia (1) Myelodysplastic Syndromes (1) Refractory Idiopathic Aplastic Anemia (1) Acute Lymphoblastic Leukemia (1) Acute Myeloid Leukemia (1)

Modalities

small molecule (7), mixed (2), other (1), protein or peptide (1)

Companies

M.D. Anderson Cancer Center (1) Dana-Farber Cancer Institute (1) Nantes University Hospital (1) Beijing Immunochina Medical Science & Technology (1) City of Hope Medical Center (1) Memorial Sloan Kettering Cancer Center (1) Gilead Sciences (1) Jiangsu Healthy Life Innovation Medical Technology (1) Ekaterina Laukhtina (1) West China Second University Hospital (1) Princess Maxima Center for Pediatric Oncology (1)

Related targets

RRM1 (10) RRM2B (10) RRM2 (10) POLD4 (10) POLB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.